Protesters are to gather outside AstraZeneca's UK sites to demand the pharmaceutical firm shares its coronavirus vaccine technology.

They're planned to gather outside its Cambridge headquarters, the Macclesfield campus, and at the University of Oxford, which worked with AstraZeneca to develop the vaccine.

The demonstration on Tuesday, organised by Global Justice Now, is calling for the British-Swedish company to openly licence its jab and commit to sharing the technology with the World Health Organisation (WHO).

Global Justice Now said the action, which coincides with AstraZeneca’s annual general meeting, also seeks to persuade Oxford University to make all of its future medical innovations open-licenced.

Nick Dearden, director of Global Justice Now, said: “Scientists at Oxford University, a publicly-funded institution, developed this lifesaving vaccine through a research and development process that was 97 per cent publicly funded.

“The resulting vaccine should have been openly accessible to everyone, but AstraZeneca swooped in and privatised it.

“The UK is reaping the benefits of the highly effective vaccines that are now available, but people in low and middle-income countries are still dying daily by the thousands from Covid-19.

The Prime Minister visiting the AstraZeneca site in Macclesfield on April 6

“AstraZeneca like to portray themselves as the good guys, but they’ve boycotted attempts to pool the vaccine knowledge they control just like all the other Pharma giants – and now claim they have no time to share this knowledge globally.

“Today, we’re demanding AstraZeneca pool this publicly created knowledge so the whole world can ramp up production of these vaccines.”

The social justice organisation claimed that AstraZeneca has not yet joined WHO’s Covid-19 Technology Access Pool, which facilitates the sharing of technology for vaccines and treatments.

It comes as the group put up posters at bus stops across the UK over the weekend to highlight the level of public investment in vaccine research and development and the profits made by pharmaceutical companies.

AstraZeneca has been contacted for comment.